Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:person
|
| gptkbp:awardReceived |
gptkb:Rare_Champion_of_Hope_Award
gptkb:Roscoe_O._Brady_Award_for_Innovation |
| gptkbp:developedBy |
Aldurazyme (laronidase)
enzyme replacement therapy for MPS I |
| gptkbp:education |
gptkb:Pomona_College
gptkb:University_of_California,_Los_Angeles |
| gptkbp:employer |
gptkb:Ultragenyx_Pharmaceutical
|
| gptkbp:field |
genetics
pediatrics |
| gptkbp:founded |
gptkb:EveryLife_Foundation_for_Rare_Diseases
|
| https://www.w3.org/2000/01/rdf-schema#label |
Emil D. Kakkis
|
| gptkbp:knownFor |
enzyme replacement therapy
rare disease drug development |
| gptkbp:nationality |
gptkb:American
|
| gptkbp:notableWork |
gptkb:Aldurazyme
founding EveryLife Foundation for Rare Diseases |
| gptkbp:occupation |
gptkb:physician
gptkb:researchers biologist |
| gptkbp:position |
CEO
|
| gptkbp:bfsParent |
gptkb:Ultragenyx_Pharmaceutical
gptkb:Ultragenyx |
| gptkbp:bfsLayer |
7
|